Latest urothelial cancer News

AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
Imfinzi plus Imdelltra demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small…
New treatment option on the PBS for locally advanced or metastatic bladder cancer
Expansion of immunotherapy PBS listing to treat multiple new cancers
New and expanded cheaper medicines for severe and life-threatening conditions
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec)…
Study finds mutations, DNA structures driving bladder cancer
Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment
New therapy will revolutionise treatment of urothelial and bladder cancers
Cheaper medicines for cervical cancer, urotherial cancer and spinal muscle atrophy
New approval for trial of Immutep’s ‘efti’ with Merck’s PD-L1 inhibitor
Immutep announces new collaboration for cancer treatment combination
Heartburn treatment a poor match to cancer drug